Post-TNFalpha
| Zeile 1: | Zeile 1: | ||
{{up|PHA Biologicals}} | {{up|PHA Biologicals}} | ||
{{qt|Pentoxyfylline}} | {{qt|Pentoxyfylline}} | ||
| + | ---- | ||
| + | etanercept, infliximab, adalimumab | ||
| + | ---- | ||
{{tp|p=32278362|t=2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed |pdf=|usr=}} | {{tp|p=32278362|t=2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed |pdf=|usr=}} | ||
| Zeile 8: | Zeile 11: | ||
{{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}} | {{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}} | ||
{{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}} | {{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}} | ||
| + | {{tp|p=C7334116|t=2020. Etanercept/methotrexate: COVID-19: case report.|pdf=|usr=015}} | ||
| + | {{tp|p=32680535|t=2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.|pdf=|usr=014}} | ||
| + | {{tp|p=33036639|t=2020. Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.|pdf=|usr=020}} | ||
| + | {{tp|p=33294881|t=2020. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.|pdf=|usr=022}} | ||
| + | {{tp|p=33004419|t=2020. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community.|pdf=|usr=019}} | ||
| + | {{tp|p=C7648207|t=2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.|pdf=|usr=023}} | ||
Aktuelle Version vom 12. April 2021, 15:37 Uhr
| PHA Biologicals |
| Pentoxyfylline |
etanercept, infliximab, adalimumab
32278362 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
32382744 2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.
32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
32554621 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
32553760 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.
C7334116 2020. Etanercept/methotrexate: COVID-19: case report.
32680535 2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.
33036639 2020. Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.
33294881 2020. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.
33004419 2020. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community.
C7648207 2020. Adalimumab/anakinra/dexamethasone: COVID-19 infection cytomegalovirus reactivation and off-label use: case report.
